Vitiligo Treatment Guidelines

Introduction to Vitiligo Treatment

A diagnosis of vitiligo can be made in primary care based on symmetrical, well-defined white patches, with atypical presentations referred for expert dermatological assessment, and blood tests, including thyroid function testing, should be considered due to the high prevalence of autoimmune thyroid disease in patients with vitiligo 1

Topical fluticasone used alone for 9 months induced mean repigmentation of only 9% in clinical studies, with side effects including skin atrophy, hypertrichosis, and acne 1
Potent or very potent topical corticosteroids can be used for limited areas, with monitoring for skin atrophy, for a maximum of 2 months 1
The British Association of Dermatologists recommends against using topical calcipotriol monotherapy as it has no effect in vitiligo 1

Topical pimecrolimus gave 50-100% repigmentation in 8/10 patients compared with 7/10 patients treated with clobetasol in a left-vs-right comparison over 8 weeks 1
Topical calcineurin inhibitors (tacrolimus/pimecrolimus) are alternatives to topical steroids, particularly useful for facial areas and in children, with similar efficacy to potent corticosteroids but with fewer side effects 1

The combination of fluticasone and UVA induced mean repigmentation of 31%, significantly better than either treatment alone 1
Combining topical corticosteroids with calcipotriol may be more effective than either agent alone, with a small study showing >50% repigmentation in 4/15 cases with combination therapy compared to 2/15 with betamethasone alone 1
Combination therapy (corticosteroids + NB-UVB) is recommended for hands and feet, with surgical options considered for stable, treatment-resistant patches 1

The British Association of Dermatologists recommends narrowband UVB (NB-UVB) phototherapy for widespread vitiligo not responding to topical treatments, ideally reserved for patients with darker skin types (III-VI), with patients informed that NB-UVB does not alter the natural history of vitiligo and has variable response rates, particularly poor on hands and feet 1
NB-UVB is considered superior to PUVA for vitiligo treatment, with better repigmentation rates and fewer side effects, according to the British Association of Dermatologists 1, 2
The British Association of Dermatologists suggests a treatment frequency of 2-3 times weekly on non-consecutive days for NB-UVB phototherapy, with a maximum cumulative dose limit of 200 treatments for skin types I-III, but can be higher for skin types IV-VI with patient consent 1

For facial lesions, the first choice is topical calcineurin inhibitors (tacrolimus/pimecrolimus), with alternative options including potent topical corticosteroids and adding NB-UVB phototherapy for resistant cases 1
For body lesions, the first choice is potent topical corticosteroids, with options for widespread areas including NB-UVB phototherapy and combination therapy (corticosteroids + calcipotriol) for resistant cases 1
For hands and feet, combination therapy (corticosteroids + NB-UVB) is recommended, with surgical options considered for stable, treatment-resistant patches 1

For very fair skin (types I-II), cosmetic camouflage and sunscreens may be considered rather than active treatment, and for extensive vitiligo in darker skin types, depigmentation with p-(benzyloxy)phenol may be considered as a last resort 1
For children with vitiligo, topical calcineurin inhibitors are preferred over potent corticosteroids, and NB-UVB may be used if topical therapies are inadequate 1
For patients with small cell lung cancer (SCLC) receiving chemotherapy, consider treating vitiligo between chemotherapy cycles when immune function is less compromised, and avoid aggressive vitiligo treatments during periods of severe neutropenia 3

Serial clinical photographs are essential for tracking progress in patients with vitiligo, and the Vitiligo Area Scoring Index (VASI) provides a more accurate measurement of disease extent 1
Regular follow-up with serial clinical photographs is necessary to track progress in patients with vitiligo, and assessment of psychological and quality of life effects should be made, with appropriate interventions offered to patients 1
Psychological support should be offered to improve coping mechanisms, and common pitfalls to avoid include prolonged continuous use of potent corticosteroids, using calcipotriol as monotherapy, inadequate treatment duration, neglecting psychological aspects of the condition, and failing to adjust treatment based on anatomical location response 1